Over atMorgans, its analysts have an add rating and $330.75 price target on the company's shares. This implies potential upside of almost 15% for investors from current levels.
The broker recently named CSL as one of itsBest Calls to Action. It notes that these are "stocks that present compelling buying prospects right now."
Elsewhere, analysts atMacquariehave an outperform rating and $334.00 price target on CSL stock. This suggests that upside of approximately 16% is possible over the next 12 months.
In addition, the broker has previously stated its belief that CSL's shares could hit $500 within three years. This is based on its forecast for strong double-digit earnings growth for the foreseeable future thanks to the CSL Behring plasma business.
What else?
UBSis also bullish on CSL and has a buy rating and $330.00 price target on its shares, andJardenhas an overweight rating and $329.62 price target on them.
But the most bullish broker is arguablyBell Potter, which has a buy rating and $345.00 price target. This implies potential upside of almost 20% for investors in 2025.
Commenting on its buy rating, the broker said:
(20min delay)